MedImmune sued over motavizumab conflict; New safety standards needed in biotech labs;

 @FierceBiotech:  InterMune to chop 60 workers in wake of FDA's rejection. Article | Follow @FierceBiotech

 @JohnCFierce: Schwan on biosimilars: "It's a different ball game and we expect a much lesser penetration of biosimilars." Follow @JohnCFierce

> Peter Roelvink, the former head of MedImmune's infectious disease department, filed a lawsuit against the Gaithersburg, MD-based drug developer saying the company fired him after he questioned the test results on a next-generation version of Synagis. According to the Washington Business Journal, Roelvink says he raised serious issues regarding the program for motavizumab at a time the company was pushing for results. An advisory committee is scheduled to meet Wednesday to review the therapy for RSV. Story

> The people who work in biotech labs are exposed to "imponderable hazards," writes the New York Times' Andrew Pollack. And there have been new calls to create better safety standards for the labs. Report

> South San Francisco-based VaxGen has struck a deal to acquire diaDexus in a stock-for-stock transaction. Report

> Maxygen plans to buy back another $10 million in shares. Story

> Miami-based Heat Biologics says that it has closed an initial funding round led by Brightline Ventures for an unspecified amount of cash. The money will be used to push two programs into the clinic in 2011. Release

> NuTech Medical says it will buy an 11-acre campus in Birmingham that had housed a general contractor. Report

And Finally... A new survey from the Iowa Biotechnology Association finds that half of all the college-level biotech students in the state would like to stay in Iowa, but many fear they won't find jobs. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.